Five Hurdles for Biotech

Five Hurdles for Biotech
The science is hot and the stocks are up. Here’s what’s needed to deliver on the promise.

Puncturing The ImClone Hype

Puncturing The ImClone Hype
Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe.

A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.